The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer
Open accessAbstract
BACKGROUND: Several recent studies have demonstrated that microRNAs (miRNAs) are stably detectable in plasma/serum. We tested miR-221 and miR-375, which are frequently reported to be highly and poorly expressed in pancreatic cancer (PCa), as candidates for plasma biomarkers in PCa. METHODS: This study was divided into three parts: (1) Confirmation of higher miR-221 levels in primary PCa tissue and cell lines than normal pancreatic tissues. (2) Evaluation of plasma miR-221 and miR-375 concentrations by comparing results from 47 consecutive PCa patients and 30 healthy volunteers. (3) Evaluation of the assay for monitoring tumour dynamics in PCa patients. RESULTS: (1) Expression of miR-221 was significantly higher in PCa tissues and cell lines than normal pancreatic tissues. (2) Plasma miR-221 concentrations were significantly higher in PCa patients than that in benign pancreatic tumours (P=0.016) and controls (P<0.0005), while plasma miR-375 concentrations tended to be lower in PCa patients (P=0.064), and the miR-221/miR-375 ratio was significantly higher (P<0.0001) in PCa patients than in controls. (3) Plasma miR-221 concentrations were significantly reduced in postoperative samples (P=0.018). Furthermore, PCa patients with high plasma miR-221 concentrations had significant correlation with distant metastasis (P=0.041), and non-resectable status (P=0.021). CONCLUSION: Plasma miR-221 could be a useful biomarker for cancer detection, monitoring tumour dynamics and predicting malignant outcomes in PCa patients, and may contribute to clinical decision making in PCa treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.107821 · Cited by 1,934
Understanding diagnostic tests 3: receiver operating characteristic curves
Akobeng, A. K. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2006.00178.x · Cited by 1,882 · cited 3×
“From the results, patients who presented with high plasma miR-221 concentrations, with a cutoff value of 2.097 10 2amol ml 1 calculated by the Younden index (Akobeng, 2007), showed significant correlations with the presence of distant metastasis (P¼ 0.041) and non-resectable status (P¼ 0.021).”
MethodInfluentialBlood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., Tait, J. F., & Tewari, M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0370 · Cited by 879
Hu, Z., Chen, X., Zhao, Y., Tian, T., Jin, G., Shu, Y., Chen, Y., Xu, L., Zen, K., Zhang, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9342 · Cited by 798
Cited by
Circulating Exosomal microRNAs as Biomarkers of Colon Cancer
Ogata-Kawata, H., Izumiya, M., Kurioka, D., Honma, Y., Yamada, Y., Furuta, K., Gunji, T., Ohta, H., Okamoto, H., Sonoda, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092921 · Cited by 809
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Madhavan, B., Yue, S., Galli, U., Rana, S., Gross, W., Müller, M., Giese, N. A., Kalthoff, H., Becker, T., Büchler, M. W., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29324 · Cited by 495
Circulating MicroRNAs in Cancer: Potential and Challenge
Cui, M., Wang, H., Yao, X., Zhang, D., Xie, Y., Cui, R., & Zhang, X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00626 · Cited by 418
Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy
Cheng, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.001 · Cited by 334
Metadata
- Authors
- Kawaguchi, T., Komatsu, S., Ichikawa, D., Morimura, R., Tsujiura, M., Konishi, H., Takeshita, H., Nagata, H., Arita, T., Hirajima, S., Shiozaki, A., Ikoma, H., Okamoto, K., Ochiai, T., Taniguchi, H., & Otsuji, E.
- Venue
- British Journal of Cancer
- Published
- 2013-01-17
- Volume
- 108
- Issue
- 2
- Pages
- 361-369
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2014200421
- Cited by
- 214
- References
- 6
- FWCI
- 9.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. https://app.cochat.ai/papers/10.1038/bjc.2012.546
- The paper
- Kawaguchi, T., Komatsu, S., Ichikawa, D., Morimura, R., Tsujiura, M., Konishi, H., Takeshita, H., Nagata, H., Arita, T., Hirajima, S., Shiozaki, A., Ikoma, H., Okamoto, K., Ochiai, T., Taniguchi, H., & Otsuji, E. (2013). Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2012.546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.